Revenue
2018
2019
2020
2021
2022
2023
2024
2025
Arcturus Therapeutics Holdings Inc. (ARCT)
Price$15.82Cached quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $82.0M | $152.3M | $166.8M | $206.0M | $12.4M | $9.5M | $20.8M | $15.8M |
| Research & development | $112.2M | $195.2M | $192.1M | $147.8M | $173.8M | $57.8M | $33.6M | $17.0M |
| Operating expenses | $158.3M | $248.0M | $245.0M | $193.8M | $215.2M | $81.1M | $46.3M | $37.6M |
| Operating income | −$76.3M | −$95.7M | −$78.2M | $12.2M | −$202.9M | −$71.5M | −$25.5M | −$21.8M |
| Operating margin | −92.96% | −62.81% | −46.89% | 5.91% | −1,641.33% | −749.81% | −122.72% | −138.46% |
| EBITDA | −$73.2M | −$92.1M | −$75.2M | $13.7M | −$201.7M | −$70.6M | −$24.8M | −$21.2M |
| EBITDA margin | −89.28% | −60.49% | −45.11% | 6.65% | −1,631.68% | −740.56% | −119.43% | −134.76% |
| Net income | −$65.8M | −$80.9M | −$29.7M | $9.3M | −$203.7M | −$72.1M | −$26.0M | −$21.8M |
| Net profit margin | −80.19% | −53.14% | −17.82% | 4.54% | −1,647.98% | −756.35% | −125.02% | −138.29% |
| Basic EPSper basic share | -$2.40 | -$3.00 | -$1.12 | $0.35 | -$7.74 | -$3.55 | -$2.15 | -$2.16 |
| Diluted EPSper diluted share | -$2.40 | -$3.00 | -$1.12 | $0.35 | -$7.74 | -$3.55 | -$2.15 | -$2.16 |
Owners
Reported shareholders
11.62%of listed shares
FEDERATED HERMES, INC.3.3M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
FEDERATED HERMES, INC. | 11.62%3.3M shares |
ARK Investment Management LLC | 10.21%2.9M shares |
BlackRock, Inc. | 9.20%2.61M shares |
Sumitomo Mitsui Trust Group, Inc. | 6.91%1.96M shares |
Amova Asset Management Americas, Inc. | 6.90%1.96M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 3.92%1.11M shares |
TWO SIGMA INVESTMENTS, LP | 3.84%1.09M shares |
VANGUARD PORTFOLIO MANAGEMENT LLC | 3.35%951.58K shares |
GEODE CAPITAL MANAGEMENT, LLC | 2.44%693.66K shares |
AQR CAPITAL MANAGEMENT LLC | 2.37%675.01K shares |
JACOBS LEVY EQUITY MANAGEMENT, INC | 2.28%647.51K shares |
STATE STREET CORP | 2.00%569.6K shares |
UBS Group AG | 1.73%490.63K shares |
Chivukula Pad | ≈1.53%435.33K shares |
D. E. Shaw & Co., Inc. | 1.38%392.36K shares |
Empire Life Investments Inc. | 1.29%366.22K shares |
Hennion & Walsh Asset Management, Inc. | 1.22%346.21K shares |
MILLENNIUM MANAGEMENT LLC | 1.19%337K shares |
GOLDMAN SACHS GROUP INC | 1.09%309.86K shares |
BNP PARIBAS FINANCIAL MARKETS | 0.92%261.79K shares |
Percentages use 28.42M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Aug 15, 2025Form 4/A | SASSINE ANDYChief Financial Officer | BuyCommon Stock | 1.2K | $16.56 | $20.5K | 221.8K |
| Aug 15, 2025Form 4 | SASSINE ANDYChief Financial Officer | BuyCommon Stock | 1.2K | $16.56 | $20.5K | 221.8K |
| Oct 15, 2024Form 4 · 10b5-1 | Chivukula PadChief Scientific Officer & COO | SellCommon Stock | 12.0K | $20.76 | $249.1K | 435.3K |